In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...

Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax ... Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

Moderna’s shrinking revenue, expected losses, and weak financial score make it a stock to sell. Looking for more actionable ... In this article, we are going to take a look at where Moderna, Inc.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...